X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Vetter Wins Frost & Sullivan’s 2021 Global Customer Value Leadership Award, and Looks Back on a Stable Year Under Ongoing Pandemic Circumstances

Content Team by Content Team
14th December 2021
in News
Vetter Wins Frost & Sullivan’s 2021 Global Customer Value Leadership Award, and Looks Back on a Stable Year Under Ongoing Pandemic Circumstances

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has been awarded the Frost & Sullivan’s 2021 Global Customer Value Leadership Award in the aseptic fill & finish market for the company’s provision of high-value to its customers. The award, presented annually by the prestigious international growth and consulting firm focuses on both business and customer impact and takes into account the current situation as well as trends in the market.

The award decision process involved three major steps: first, Frost & Sullivan examined service providers from the global pharmaceutical and biotech industry and their focus on both business and customer impact. The examination incorporates ten criteria including financial performance, operational efficiency, growth potential, price/performance value as well as customer service experience. Second, an in-depth interview was conducted with a respective senior management representative based on a qualitative and quantitative measurement of the criteria as well as current market conditions and trends. Third, a nomination compendium was created that contains all the necessary substantiation and justification and was thoroughly reviewed by Frost & Sullivan’s Best Practices Recognition committee.

Vetter was recognized for providing high customer value, in particular, the company’s best practices in collaboration with global customers. The committee further acknowledged the CDMO for the significant role it plays in the success of its clients by providing crucial support from the early development phase of drugs through regulatory approval and market supply worldwide.

In explaining its decision, Frost & Sullivan’s Industry Expert Surbhi Gupta said, “Vetter is renowned for its quality, innovation and loyalty as a strategic partner for pharmaceutical and biotech clients. The company offers end-to-end development and manufacturing services for variable batch sizes and drug-delivery systems, backed by flexible, scalable, and reproducible processes. Thus, we believe Vetter to be a well-qualified recipient of this award.”

Vetter Managing Director Peter Soelkner was delighted to hear of the decision. “We always make our best efforts to provide customers with state-of-the-art services that help them improve the quality of life for patients worldwide. Our contributions to those mutual partnerships are intended to help secure their success in the global marketplace.” Managing Director Thomas Otto emphasized, “This recognition by Frost & Sullivan, one of the most prestigious international consulting firms, represents an impressive achievement. However, we do not view the award as an end in itself. Rather, it is a justification of our business model of resolute customer orientation and further acts as motivation for our ongoing company development.”

Vetter looks back on a year of stable company performance
The CDMO has attained a number of achievements throughout 2021, an especially rewarding accomplishment given the many difficulties presented by the still continuing coronavirus pandemic. These include ongoing expansion projects into the company’s development, manufacturing, and packaging resources alongside associated processes such as quality control and storage capacities.

In March, the company opened a new business entity in Shanghai, China. The new office, now its fourth in the Asia Pacific (APAC) region, increases the visibility of Vetter’s presence in China and underlines its importance as an important strategic market to Vetter.

Additionally, in the fall, together with Syntegon, Vetter was honored by the Parental Drug Association for a joint development project that advances the production of (bio)pharmaceuticals. The collaboration resulted in a highly flexible and fully automated production cell.
The company’s new site in Rankweil, Austria, which is a European counterpart to its existing clinical manufacturing site near Chicago, has been modified to the high Vetter quality standards and is currently awaiting its manufacturing authorization by the Austrian Agency for Health and Food Safety (AGES).

Another significant company-wide milestone was reached with the attainment of climate-neutrality and elimination of a CO2 footprint. Vetter’s production sites and sales offices in Austria, the US, and Asia have followed the example of its sites in Germany where climate neutrality was already achieved in the past year.

Previous Post

FDA clears AstraZeneca's Covid antibody treatment for immunocompromised

Next Post

Hoth Therapeutics Sign API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Hoth Therapeutics Sign API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT

Hoth Therapeutics Sign API and Drug Product Contracts with WuXi STA to Advance Manufacturing of HT-KIT

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In